TJ Talks

Tumori Journal
  • 0.0 (0)
  • MEDICINE
  • UPDATED MONTHLY

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal. The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care. TJ Talks will be available from September on our website and on the best podcast platforms. Follow us on Twitter and LinkedIn to always be updated on cancer research and clinical practice in oncology!

  1. Tackling the clinical challenges of GU Oncology

    FEB 2

    Tackling the clinical challenges of GU Oncology

    From advances in the screening of prostate cancer to the management of the genitourinary tumors, the GU oncology addresses ever more clinical challenges.  What are the most relevant challenges in the management of the prostate cancer population? "It is crucial to balance the right treatment strategy with the right endpoint for patients": Professor Silke Gillessen gets straight to the point of the question posed by Dr Giuseppe Procopio, Head of the Department of Genitourinary Medical Oncology Unit at IRCCS National Cancer Institute Milan, and Editor of the GU Section of the Tumori Journal. The guest expert of this TJ Talks podcast is Silke Gillessen, Medical and Scientific Director of the Oncology Institute of Southern Switzerland and Full Professor at University of Italian Switzerland, focusing her research in genitourinary areas. In terms of endpoints - she continues - overall survival is the gold endpoint. But when it comes to metastatic prostate cancer, it is necessary to aim for a mix of quality of life, which is very important, and oncological outcomes. These should include improvements related to patients' quality of life, such as time to progression and time to symptomatic events. Patients remind us that we must think not only about the disease, but also about their well-being. Learn more about the genitourinary cancer care scenario from one of the leading voices in the field. Enjoy your listening! See omnystudio.com/listener for privacy information.

    8 min
  2. Primary and Surrogate Endpoints in Clinical Trials: Implementation and Challenges in Daily Practice

    11/26/2025

    Primary and Surrogate Endpoints in Clinical Trials: Implementation and Challenges in Daily Practice

    The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.  In this TJ Talks dedicated to the hot topic of endpoints in clinical trials, Gabriele Zoppoli, Associate Professor of Medicine at University of Genoa and Internal Medicine Consultant at Policlinico San Martino (Genoa) meet Erman Akkus, MD at Ankara University, Faculty of Medicine, Department of Medical Oncology. Alongside “primary clinical endpoints”, which concern overall survival and quality of life, surrogate endpoints are early or indirect measures of these primary endpoints, such as progression-free survival and response rate. Their purpose? To facilitate clinical trials and drug approval, but surrogate endpoints are still an active area of research and are the subject of debate in oncology. Meanwhile, patients' perceptions are waiting to be taken more seriously. Get insights, listen to the TJ Talks podcast See omnystudio.com/listener for privacy information.

    13 min
  3. Pharmaco-prevention in Breast Cancer: a strategy to halve the incidence of a potentially fatal disease

    10/23/2025

    Pharmaco-prevention in Breast Cancer: a strategy to halve the incidence of a potentially fatal disease

    Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection. In this TJ Talks podcast, together with Prof. Andrea De Censi, director of the Breast Unit at the Champalimaud Foundation in Lisbon, Portugal, here in conversation with Prof. Antonino Musolino (director of the Medical Oncology Unit at the IRCCS-Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Forlì-Cesena), we will examine what practical solutions can bridge the gap between pharmacological prevention, indication and adoption, with a look at the future perspectives in this setting. Enjoy your listening! See omnystudio.com/listener for privacy information.

    14 min
  4. The last journey: the invisible needs of migrant patients between palliative care and the need for protection

    09/25/2025

    The last journey: the invisible needs of migrant patients between palliative care and the need for protection

    Stories of foreign cancer patients who ask to return to their country at the end of their lives: their deep desire to see their loved ones one last time is intertwined with medical, legal and financial issues that seem insurmountable. In this TJ Talks, Dr Sergio Defendi, director of Palliative Care and Home Care at Asst Crema, who has been providing assistance with end-of-life travel for years, discusses this issue together with Dr Luca Zambelli, from the Palliative Care Unit of the IRCCS National Cancer Institute Foundation in Milan. How should the responsibility for end-of-life repatriation be managed? Clinical uncertainty, the legal issue of the use of certain drugs, and the protection of patients and accompanying doctors should be addressed in guidelines or care pathways that deal with this sensitive issue. This is the next challenge for the oncology community. Enjoy your listening! See omnystudio.com/listener for privacy information.

    17 min
  5. The last journey: il bisogno invisibile dei pazienti migranti fra cure palliative e necessità di tutela

    09/25/2025

    The last journey: il bisogno invisibile dei pazienti migranti fra cure palliative e necessità di tutela

    Storie di pazienti oncologici stranieri che chiedono di tornare nel loro Paese per il fine vita: attorno al desiderio profondo di rivedere ancora una volta i propri cari si intrecciano questioni mediche, legali, finanziarie che sembrano insormontabili. A parlarne in questo episodio di TJ Talks è il dr. Sergio Defendi, direttore S.C. Cure Palliative e Adi di Asst Crema, che da anni si occupa di dare assistenza nei viaggi per il fine vita, insieme al dr. Luca Zambelli, dell’Unità Cure Palliative Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.   Come gestire la responsabilità di un rimpatrio per il fine vita? L'incertezza clinica, la questione legale dell'uso di alcuni farmaci e la tutela dei pazienti e dei medici che li accompagnano dovrebbero trovare spazio in linee guida o percorsi di cura che affrontino questo delicato problema, destinato a crescere. Una prossima sfida per la comunità oncologica. Buon ascolto! See omnystudio.com/listener for privacy information.

    18 min
  6. The role of real-world trials and single-arm trials in the drug approval process

    07/17/2025

    The role of real-world trials and single-arm trials in the drug approval process

    Looking forward to the future, the trends and challenges regarding the increasing utilization of real-world data and single-arm trials in the oncology drug approval pathway by European Medicines Agency (EMA) is very important, especially in the context of personalized medicine that will become the future. Dr. Francesco Pignatti, Scientific advisor for Oncology in the Human Medicine Division of the European Medicines Agency, is the guest of this TJ Talks episode - led by dr. Luca Moscetti, Adjunct Professor in Oncology at the Residency Program in Oncology at the University of Modena Reggio Emilia - that addresses the relevant question for cancer patients about the EMA’s position on the use of real-world data in drug approvals. It emerged during the thick TJ Talks that for big changes in the use of real-world data much will also depend on the uncertainty one is willing to accept in a specific situation. Single-arm trial, for example, comes with a lot of uncertainty, mostly about the time related endpoints like survival, then you have to you tend to accept them more where you have high unmet medical needs. The goal of the scientific community is to focus the efforts on what really matters, trying to be more efficient, cleverer and to design quality criteria that are fit for purpose and that are proportionate to the objectives. Regulators, academics and the sponsors need to facilitate this type of research, maximising the opportunities that come from its data. Enjoy the listening here See omnystudio.com/listener for privacy information.

    21 min
  7. Oncologia di precisione: approccio multidisciplinare e intelligenza artificiale per terapie personalizzate

    06/27/2025

    Oncologia di precisione: approccio multidisciplinare e intelligenza artificiale per terapie personalizzate

    Le parole del prof. Paolo Marchetti restituiscono il quadro complesso dell’oncologia di precisione con il ritmo epico delle grandi imprese di frontiera.  E’ lui - Professore Ordinario di Oncologia Medica dell’Università degli Studi di Roma “La Sapienza”, Direttore Scientifico di IDI-IRCCS, Presidente della Fondazione per la Medicina Personalizzata e promotore dello studio clinico Trial Rome  - grande esperto dell’oncologia di precisione in Italia, l’ospite di questo episodio di TJ Talks, condotto dal prof. Giancarlo Pruneri.   Un concetto ampio quello dell’oncologia di precisione, basato sullo studio del genoma delle cellule tumorali, per illustrare il quale  il prof. Marchetti sottolinea i vantaggi clinici che l’applicazione di questo percorso comporta, senza dimenticare quei fattori perturbanti la possibile risposta a un determinato farmaco: come le interazioni, le modificazioni del microbiota, stili di vita e attività fisica. Un quadro complesso che promuove il confronto tra clinici, biologi molecolari, patologi e genetisti su un numero crescente di dati eterogenei.   E l’intelligenza artificiale? Fondamentale per gestire i dati provenienti da studi clinici a livello europeo, o presenti in piattaforme nazionali; indispensabile per comprendere i potenziali meccanismi di resistenza ai farmaci e per la sintesi delle conoscenze più appropriate e personalizzate per la cura del paziente. See omnystudio.com/listener for privacy information.

    28 min
  8. Precision Oncology: Multidisciplinary Approach and Artificial Intelligence for Personalized Therapies

    06/27/2025

    Precision Oncology: Multidisciplinary Approach and Artificial Intelligence for Personalized Therapies

    In this episode of TJ Talks, the guest is Professor Paolo Marchetti, a well-known expert in precision oncology in Italy, Full Professor of Medical Oncology at the University of Rome "La Sapienza", Scientific Director of IDI-IRCCS, President of the Foundation for Personalized Medicine and promoter of the Trial of Rome clinical study. Precision oncology is a broad concept based on the study of the genome of tumour cells and Prof. Marchetti – interviewed by Prof. Giancarlo Pruneri -  highlights the clinical advantages of applying this path, without forgetting the factors that interfere with the possible response to a given drug: such factors include interactions, alterations of the microbiota, lifestyle and physical activity, making the scenario even more complex and fostering comparison among clinicians, molecular biologists, pathologists and geneticists on an ever-increasing number of heterogeneous data. In precision oncology, the role of artificial intelligence in managing data from clinical trials is essential to understand potential mechanisms of drug resistance and synthesize the most appropriate and personalized knowledge for patient care. See omnystudio.com/listener for privacy information.

    13 min
See All (17)

Trailer

About

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal. The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care. TJ Talks will be available from September on our website and on the best podcast platforms. Follow us on Twitter and LinkedIn to always be updated on cancer research and clinical practice in oncology!

Information

  • Creator
    Tumori Journal
  • Years Active
    2024 - 2026
  • Episodes
    17
  • Rating
    Clean
  • Show Website
    TJ Talks